Probability of EULAR response categories (none, moderate, good) given mutually exclusive ACR response categories (ACR < 20, ACR 20 - <50, ACR 50 - <70, and ACR 70+).
acr2eular
A matrix where each row shows the probability that a particular responder in an ACR category will have a given EULAR response. Probabilities are based on observed relationships in the VARA database.
Stevenson, Matt, et al. "Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation." Health Technology Assessment 20.35 (2016): 1-610.